Research Articles | Page 19 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? Oct 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of Oct 2020 Bone Marrow Transplantation Aplastic Anemia
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp Sep 2020 Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes Sep 2020 Blood Myelodysplastic Syndromes (MDS)
Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic Syndromes Sep 2020 Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation Myelodysplastic Syndromes (MDS)
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? Sep 2020 Expert Review of Hematology Myelodysplastic Syndromes (MDS)
Is blood transfusion safe during the COVID-19 pandemic? Sep 2020 Future Science OA Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH)
Novel therapeutic choices in immune aplastic anemia Sep 2020 F1000Research Aplastic Anemia
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. Sep 2020 PloS One Paroxysmal Nocturnal Hemoglobinuria (PNH)
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience Sep 2020 Leukemia & Lymphoma Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)